Chinese biotech startup Binhui Biopharm has secured about $47 million in a Series B+ round of financing as it is rolling out clinic trials of its self-developed novel oncolytic virus drug candidate BS001 (OH2).
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
